The FDA Proposes Adding Five Of 31 Drug Substances To 503A Bulks List
Executive Summary
FDA proposal would allow traditional compounding from five drug substances based on medical need, but not from another 26.
You may also be interested in...
US FDA 'Bulks Up' 503B Outsourcing Drug List By Proposing Four First-Time Additions
The US FDA has proposed allowing outsourcing facilities to compound from four drug substances, but not from 19 others that it says already are available in FDA-approved drug products. Compounding pharmacies also would be allowed to compound from two of the four drug substances.
Nine More FDA Bulk Compounding Denials Proposed Post-Vasopressin
Expected flurry of FDA proposals against 503B compounding from bulk drug substances follows vasopressin court ruling.
The US FDA Reverses Decision And Allows Oxitriptan Compounding For Now
The US FDA says new information brought to light by pharmacists and caregivers on compounded oxitriptan prompted the agency to reconsider its decision to exclude the substance from the 503A bulks list. Oxitriptan was placed on the do not compound list in February.